E-mail this pagePrint
The World Hypertension Market 2008-2023 Publication Date   January 2008 Publisher   VISIONGAIN Product Type   Report Pages   not applicable ISBN Number   not applicable Product Code   VISG02

The market for hypertensives - led by the angiotensin II antagonists - is one of the largest and most profitable in the global pharmaceutical market, with total anti-hypertensive sales of $36600m in 2006. Hypertension, or high blood pressure, is a worldwide epidemic: Visiongain predict that by 2025 there will be more than 1.5 billion sufferers of this disease worldwide. Modern lifestyles, such as poor diet and lack of exercise, are the main contributory factors to elevated blood pressure. Consequently, the incidence and prevalence of hypertension are increasing rapidly in both developed and developing countries.

In 2005, The Lancet reported that more than 330 million adults in Europe and North America suffer from high blood pressure.
According to the World Health Organisation, approximately 80% of people with high blood pressure have additional uncontrolled cardiovascular risks.
Hypertension is also strongly age-dependent, with older people being far more susceptible.
Aging populations worldwide therefore constitute a further driver in this prominent market.

This is a market you cannot afford to ignore. Are new, potentially successful drugs going to change the market within the next 10 to 15 years? This report will tell you.

The World Hypertension Market 2008-2023 examines the market for antihypertensive drugs critically, through comprehensive primary and secondary research. In addition to consultation with experts in medical practice, academia and industry, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

The hypertension market is one of the largest in the global pharmaceutical industry, with continued prospects for high revenue generation and market growth. Nevertheless, the hypertension market is facing great challenges in terms of strong internal competition and patent expiration with a concomitant generic threat. Clearly, there are also unmet needs in this market that require urgent attention. While the angiotensin II antagonists have provided an improved balance of efficacy and tolerability in recent years, it is possible that even newer classes of antihypertensive - such as the renin inhibitors – will also provide great therapeutic and commercial scope. Given the great challenges of treating hypertension, continued investment into the development of improved treatments is required, as well as basic scientific research into the disorder. Recent developments in both the pharmaceutical industry and the pu blic sector provide scope for optimism.

Table of Contents

Chapter 1. Executive Summary - Hypertension is a Serious Cause of Mortality Worldwide

Chapter 2. Introduction to Hypertension
2.1 An Overview of Hypertension
2.2 Symptoms of Hypertension and Diagnosis of the Condition
2.3 Causes of Hypertension
2.4 Primary Hypertension
2.5 Secondary Hypertension
2.6 Pulmonary Hypertension
2.7 Epidemiology of Hypertension
2.8 Links with Other Disorders
2.9 The Treatment of Hypertension
      2.9.1 Countering Hypertension Through Changes in Diet and Lifestyle - A First Line of Attack
      2.9.2 Treatment Targets and the Selection of Drugs
      2.9.3 Beta Blockers
      2.9.4 Angiotensin Converting Enzyme (ACE) Inhibitors
      2.9.5 Calcium-Channel Blockers
      2.9.6 Angiotensin II Blockers
      2.9.7 Alpha Blockers
      2.9.8 Diuretics
      2.9.9 Tekturna/Rasilez (aliskiren) - a First-In-Class Renin Inhibitor
      2.9.10 Other Drugs
2.10 The Treatment of Pulmonary Hypertension
2.11 The Prospects for Patients

Chapter 3. The World Hypertension Market, 2008-2023
3.1 Growing Demand and Shifting Internal Dynamics in the World Anti-hypertensive Market, 2008-2023
3.2 Novartis to Become the Leading Company in the Hypertension Market by the End of the Decade
3.3 Angiotensin II Blockers to Continue Their Domination of the Anti-hypertensive Market, 2006 Onwards
3.4 Other Classes of Anti-hypertensive Drug Will Display High Revenues during 2006-2012
3.5 Calcium Channel Blockers - Declining Revenues due to Heightened Competition
3.6 Angiotensin Converting Enzyme (ACE) Inhibitors - Will This Class Be Superseded by the Angiotensin II Blockers?
3.7 Beta-Blockers - Carving a Secure Niche in a Highly Competitive Market?
3.8 Alpha Blockers Will Maintain a Respected Position in the Hypertension Market
3.9 Competition in the Anti-hypertensive Market to Become Increasingly Intense 3.10 Monotherapy or Combination Therapy?
3.10 Diuretic Agents Retain Importance

Chapter 4. The World Market for Angiotensin II Blockers, 2008-2023
4.1 Angiotensin II Blockers - Strong Growth Leads to Continuing Predominance in the Market
      4.1.1 The Angiotensin II Blockers Will Benefit From More Secure Patent Protection Than The Other Classes of Antihypertensives
      4.1.2 Other Advantages of Angiotensin II Blockers That Confer Important Benefits in the Market
4.2 Diovan to Take Market Leadership from Norvasc by 2008
      4.2.1 Diovan/Co-Diovan Benefits From High Prescription Rates in the US Market
      4.2.2 Paediatric Exclusivity Granted by FDA in 2008
      4.2.3 Approval for Reduction of Cardiovascular Death
      4.2.4 Diovan Benefits from Further Clinical Studies
      4.2.5 Recent Support from The European Society of Cardiology
      4.2.6 The AVVANCE Trial Provided Further Support for Diovan
      4.2.7 The NAVIGATOR Trial for Improved Glucose Tolerance
4.3 Cozaar/Hyzaar - High Revenues Followed by Decline
      4.3.1 Development for Diabetic Nephropathy - The RENAAL study
      4.3.2 FDA Approval for LVH
      4.3.3 Diabetic Nephropathy Approval in Japan During 2006
      4.3.4 Further Developments for Cozaar/Hyzaar
4.4 Avapro/Aprovel/Avalide to Maintain Steady Growth
      4.4.1 Avaprovel/Avapro Benefits from Continuing Development
      4.4.2 BMS Places High Emphasis on Irbesartan
      4.4.3 Sublicensing of Irbesartan for Japanese Market
4.5 Blopress - Another Strong Performer
      4.5.1 Additional FDA Approval for Blopress
4.6 Micardis Will Become a Leading Blockbuster by the End of the Decade
      4.6.1 Micardis Shows Potential Metabolic Benefits
      4.6.2 Micardis Benefits from Further Clinical Studies
      4.6.3 Further Clinical Studies May Confer a Market Advantage to Micardis
4.7 Benicar/Olmetec’s Revenue Growth Set to Continue Steadily
      4.7.1 Further Licensing Agreements for Benicar
      4.7.2 Promising Results from Further Clinical Study
      4.7.3 Sankyo Used Licensing Deals for International Marketing
      4.7.4 The ORIENT Study and Other Developments
4.8 Exforge Will Achieve Blockbuster Revenues by The End of the Decade
4.9 Other Agents Will Have an Increasing Presence in the Angiotensin II Blockers Market

Chapter 5. The World Market for Calcium Channel Blockers, 2006-2023
5.1 Increased Competition Will Lower Revenues Among the Calcium Channel Blockers
5.2 Norvasc - 2006 Hypertension Market Leader Set to Lose Dominance to Leading